Acridine derivatives

US5604237A · kind A · utility

Assignee

• Laboratoires Glaxo SA · FR

Inventors

• Bernard Dumaitre · Bobigny, FR
• Nerina Dodic · Les Ulis, FR

Key dates

• Filing date: Jun 6, 1995
• Grant date: Feb 18, 1997
• Expiry date: Jun 6, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D219/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

These are provided compounds of formula I ##STR1## wherein A represents an oxygen or a sulphur atom, a bond or a group (CH.sub.2).sub.1 NR.sup.9 (where 1 represents zero or 1 and R.sup.9 represents a hydrogen atom or a methyl group); B represents a C.sub.1-4 alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A can not be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group (CH.sub.2).sub.1 NR.sup.9, or when A represents a bond B may also represent a C.sub.2-4 alkenylene chain; R.sup.3 represents a hydrogen atom or a C.sub.1-4 alkyl group; m represents 1 or 2; R.sup.7 represents a hydrogen atom or R.sup.3 and R.sup.7 together form a group --(CH.sub.2).sub.n -- where n represents 1 or 2. These compounds can sensitize multidrug-resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an antitumor drug.